Germany’s Merck KGaA is buying a majority stake in Swiss rival Serono in a deal worth approximately $13.3 billion, according to published reports. Merck said it is buying a 64.5% stake in Serono that will give it 75.5% of voting rights, The Wall Street Journal reported. “Details of the financing will be provided prior to closing, early 2007,” a Merck spokesman said. Merck produces chemicals such as liquid crystals and drugs including cancer treatment Erbitux. Merck’s pipeline virtually dried up in June when its Parkinson’s disease drug Sarizotan failed in late-stage clinical tests. Serono’s sales increased 2.8% in the second quarter, with the company’s main product, multiple sclerosis treatment Rebif, contributing to the rise.
Belgian pharmaceutical firm UCB will co-promote its hay fever drug Xyzal (levocetirizine dihydrochloride) in the US with Sanofi-Aventis. Xyzal is UCB's successor to its blockbuster hay fever drug Zyrtec, which will lose patent US protection at the end of 2007. UCB said Sanofi-Aventis would book the sales of the drug in the US and make an upfront payment to UCB and further milestone payments related to regulatory approvals and sales. “Profits will be shared between Sanofi-Aventis and UCB,” UCB said in a statement.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.